RESTON, Va., June 22, 2021 /PRNewswire/ -- Leidos (NYSE: LDOS), a Fortune 500® science and technology leader, was recently awarded a new prime contract by the Centers for Disease Control and Prevention (CDC) to provide bioinformatics and scientific computing support services. The firm-fixed-price contract was awarded by CDC's Office of Acquisition Services and holds a maximum value of over $13 million for a period of performance of approximately five years if all options are exercised. Work will primarily be performed in Atlanta, Georgia.
"We are thrilled to expand our work with CDC into bioinformatics and high-performance scientific computing," said Liz Porter, Leidos Health Group president. "Our world-class scientific and technical team will help CDC investigate infectious pathogens and generate new discoveries to help prevent future pandemics. These discoveries could lead to transformative advances in public health and Leidos is proud to assist them in this pursuit."
Through this contract, Leidos will assist CDC's Office of Advanced Molecular Detection to expand the agency's capacity for scientific computing and bioinformatics. This includes supporting CDC personnel through information technology and high-performance analytical activities, including genomics, proteomics, high-performance computing and managing extremely large datasets.
Bioinformatics is an interdisciplinary field that combines biology, computer science and other specialties to analyze and understand biological data. Bioinformatics data sets, like those associated with DNA and amino acid sequences, can be a terabyte in size or greater. Analyzing this data requires specialized programming and advanced high-performance computing.
Leidos is a Fortune 500® information technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil, and health markets. The company's 40,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $12.30 billion for the fiscal year ended January 1, 2021. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 1, 2021, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.